A First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Intravenous (IV) Dose of GSK2831781 in Healthy Volunteers and Patients With Plaque Psoriasis

NCT02195349 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

67

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

BIOLOGICAL: GSK2831781
BIOLOGICAL: Placebo

Sponsor

GlaxoSmithKline

Collaborators

[object Object]